{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:18:27Z","timestamp":1768522707804,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coph.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T04:56:57Z","timestamp":1605157017000},"page":"173-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Embracing diversity: how can broadly neutralizing antibodies effectively target a diverse HIV-1 reservoir?"],"prefix":"10.1016","volume":"54","author":[{"given":"Andrew","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca M","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.10.004_bib0005","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.10.004_bib0010","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/science.1093137","article-title":"Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission","volume":"303","author":"Derdeyn","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.coph.2020.10.004_bib0015","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1128\/JVI.01960-08","article-title":"Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals","volume":"83","author":"Kearney","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coph.2020.10.004_bib0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11282","article-title":"Population genomics of intrapatient HIV-1 evolution","volume":"4","author":"Zanini","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.coph.2020.10.004_bib0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/viro.1997.8996","article-title":"Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles","volume":"241","author":"Shankarappa","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.coph.2020.10.004_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-018-0395-4","article-title":"HIV evolution and diversity in ART-treated patients","volume":"15","author":"van Zyl","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.coph.2020.10.004_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000120","article-title":"Review: influence of ART on HIV genetics","volume":"10","author":"Simonetti","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.004_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAD.0000000000002045","article-title":"Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth","volume":"33","author":"Brumme","year":"2019","journal-title":"Aids"},{"key":"10.1016\/j.coph.2020.10.004_bib0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fmicb.2019.00145","article-title":"Reduction of HIV-1 reservoir size and diversity after 1 year of cART among brazilian individuals starting treatment during early stages of acute infection","volume":"10","author":"Leite","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coph.2020.10.004_bib0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/tan.12867","article-title":"Barriers to HIV Cure","volume":"88","author":"Stein","year":"2016","journal-title":"HLA"},{"key":"10.1016\/j.coph.2020.10.004_bib0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/COH.0000000000000281","article-title":"Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations","volume":"11","author":"Lee","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.004_bib0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.004_bib0065","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1038\/nature24634","article-title":"Re-evaluating evolution in the HIV reservoir","volume":"551","author":"Rosenbloom","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/JVI.00755-19","article-title":"HIV diversity and genetic compartmentalization in blood and testes during suppressive antiretroviral therapy","volume":"93","author":"Miller","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coph.2020.10.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav2045","article-title":"No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: implications for HIV eradication","volume":"5","author":"Bozzi","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.coph.2020.10.004_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181680","article-title":"Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties","volume":"12","author":"Stefic","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2020.10.004_bib0085","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/COH.0000000000000484","article-title":"Lessons learned from HIV antiretroviral treatment interruption trials","volume":"13","author":"Wen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coph.2020.10.004_bib0090","doi-asserted-by":"crossref","first-page":"E1126","DOI":"10.1073\/pnas.1414926112","article-title":"Large number of rebounding\/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption","volume":"112","author":"Rothenberger","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.10.004_bib0095","first-page":"1525","article-title":"Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy","volume":"382","author":"Sneller","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2020.10.004_bib0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection","volume":"7","author":"Colby","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2020.10.004_bib0105","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.10.004_bib0110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.004_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006792","article-title":"Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals","volume":"14","author":"Clarridge","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coph.2020.10.004_sbref0120","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1172\/JCI120194","article-title":"HIV-1 latent reservoir size and diversity are stable following brief treatment interruption","volume":"128","author":"Salantes","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2020.10.004_bib0125","doi-asserted-by":"crossref","first-page":"E11341","DOI":"10.1073\/pnas.1813512115","article-title":"Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption","volume":"115","author":"Lu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.10.004_sbref0130","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","article-title":"Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2020.10.004_sbref0135","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1172\/JCI134395","article-title":"Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound","volume":"130","author":"Cale","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.10.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2020.10.004_sbref0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.004_bib0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymeth.2018.10.010","article-title":"Bispecific antibodies: potential immunotherapies for HIV treatment","volume":"154","author":"Fabozzi","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.coph.2020.10.004_bib0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/imr.12506","article-title":"HIV antibodies for treatment of HIV infection","volume":"275","author":"Margolis","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coph.2020.10.004_bib0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2019.07.007","article-title":"The potential of engineered antibodies for HIV-1 therapy and cure","volume":"38","author":"Grobben","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coph.2020.10.004_bib0165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.004_bib0170","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.004_bib0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2020.10.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.10.004_sbref0185","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1802264","article-title":"Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption","volume":"380","author":"Wang","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:54:30Z","timestamp":1761461670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220301028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":37,"alternative-id":["S1471489220301028"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.004","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Embracing diversity: how can broadly neutralizing antibodies effectively target a diverse HIV-1 reservoir?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}